CD34 and neoplasm: NPM1-mutated CAR-T cells, as well as TCR transduced T cells, should be able to specifically target all leukemic cells without reacting against healthy tissues, including CD34+ hematopoietic stem/progenitor normal cells, due to the absence of NPM1-mutated aminoacidic sequence expression, hopefully yielding potent and highly specific anti-leukemic effect, minimizing tumor resistance and “on-target/off-tumor” toxicity [4,20].